The clinical research industry is changing, and the number of protocols requiring specialty populations for early-phase clinical studies is increasing. In particular, the demand for studies on renal specialty populations has grown, given the prominent role of the renal system in excreting drugs from the body. Understanding the challenges associated with the use of specialty populations is critical to ensure that the study design will allow for the timely and successful completion of the project, while minimizing costs and safety risks.
US Food and Drug Administration. Pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling. Draft guidance. http://www.fda.gov/downloads/Drugs/Guidances/UCM204959.pdf. Published March 2010. Accessed April 4, 2017.
2.
TraynorJMactierRGeddesCCFoxJG. How to measure renal function in clinical practice. BMJ. 2006;333:733–737.
3.
SwanSKSmithWBMarburyTC. Defining normal kidney function in phase I clinical trials: an emerging issue. ASN Poster presentation, 2010.
4.
ThomasRKansoASedorJR. Chronic kidney disease and its complications. Prim Care. 2008;35:329–344.
5.
GullionCMKeithDSNicholsGASmithDH. Impact of comorbidities on mortality in managed care patients with CKD. Am J Kidney Dis. 2006;48:212–220.
6.
GoASChertowGMFanDMcCullochCEHsuCY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
